Synlogic (NASDAQ:SYBX) – Equities researchers at Piper Jaffray raised their Q3 2018 earnings estimates for shares of Synlogic in a research report issued to clients and investors on Tuesday, May 15th. Piper Jaffray analyst E. Tenthoff now anticipates that the biotechnology company will earn ($0.60) per share for the quarter, up from their previous forecast of ($0.61). Piper Jaffray has a “Buy” rating and a $15.00 price target on the stock. Piper Jaffray also issued estimates for Synlogic’s Q4 2018 earnings at ($0.64) EPS, FY2018 earnings at ($2.38) EPS, Q2 2019 earnings at ($0.74) EPS, Q3 2019 earnings at ($0.77) EPS, Q4 2019 earnings at ($0.82) EPS and FY2019 earnings at ($3.01) EPS.
Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.18. The business had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.21 million.
Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Synlogic from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Saturday. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Synlogic in a research note on Tuesday, April 17th. Finally, ValuEngine upgraded shares of Synlogic from a “strong sell” rating to a “sell” rating in a research note on Friday, April 27th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $18.20.
Shares of Synlogic opened at $9.80 on Friday, MarketBeat.com reports. Synlogic has a 52-week low of $8.76 and a 52-week high of $23.00. The firm has a market capitalization of $194.94 million, a PE ratio of -1.67 and a beta of 2.06.
Several hedge funds have recently made changes to their positions in SYBX. Farallon Capital Management LLC acquired a new position in shares of Synlogic in the 1st quarter valued at $9,146,000. Sofinnova Ventures Inc acquired a new stake in shares of Synlogic during the 1st quarter worth about $5,393,000. Artal Group S.A. acquired a new stake in shares of Synlogic during the 4th quarter worth about $5,335,000. NEA Management Company LLC increased its position in shares of Synlogic by 10.7% during the 1st quarter. NEA Management Company LLC now owns 4,229,410 shares of the biotechnology company’s stock worth $39,672,000 after purchasing an additional 410,000 shares in the last quarter. Finally, Texas Treasury Safekeeping Trust Co. acquired a new stake in shares of Synlogic during the 1st quarter worth about $975,000. Institutional investors own 56.20% of the company’s stock.
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.